PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced that, as part of its collaboration with the Lung Cancer Initiative at Johnson & Johnson1, Christopher Manley, M.D., Director of Interventional Pulmonology and Assistant Professor of Medicine at Fox Chase Cancer Center (FCCC) in Philadelphia, and Jouke T. Annema, M.D., Ph.D., Professor of Pulmonary Endoscopy, Amsterdam University Medical Center, have received the authorization from FCCC IRB to start a pilot clinical study, combining nCLE and robotic navigational bronchoscopy, using both Cellvizio and the Monarch™ Platform from Auris Health, Inc., one of the Medical Devices Companies of Johnson & Johnson, for the diagnosis of peripheral lung nodules. This study will be co-funded by the Lung Cancer Initiative at Johnson & Johnson and Mauna Kea Technologies (Clinicaltrials.gov: NCT04441749).
The AQ-Flex™ 19 Confocal Miniprobe™ (nCLE) is designed to be introduced into suspected lesions through a fine needle and is compatible with both conventional bronchoscopes and emerging endoluminal robotic bronchoscopes, such as the MonarchTM Platform. The main objective of this study is to assess feasibility and safety of nCLE during robotic navigational bronchoscopy in the analysis of peripheral lung lesions.
This study will include 25 patients with peripheral nodules.
“I am truly excited to start this feasibility study and offer two technological breakthroughs to my patients to improve the diagnosis of peripheral lung nodules,” said Dr. Christopher Manley. “The Monarch Platform is transforming the way we navigate towards peripheral pulmonary lesions, while nCLE enables the characterization at microscopic level, in vivo, and in real time inside of these lesions, located outside of the airways, through a needle. The study will assess whether the combination of these two ground-breaking technology platforms can improve the diagnostic yield relative to today’s standard of care.”
“In our recently published study2, we have shown that nCLE enables a 90% accuracy for characterizing malignancy in lung tumors and metastatic lymph nodes with substantial intra- and inter-observer agreements,” said Pr. J. T. Annema, M.D., Ph.D., Professor of Pulmonary Endoscopy, Amsterdam University Medical Center. “The combination of nCLE with robotic navigation bronchoscopy could enable real-time targeting and identification in a much larger proportion of lung tumors than with conventional bronchoscopy techniques and could significantly increase confidence in the adequacy of biopsy sampling. This study is an important step in reaching the desired future state of transitioning the patient care pathway to diagnose and treat in one setting of care.”
“The AQ-Flex™ 19 Confocal Miniprobe is the only cleared nCLE technology capable of imaging tissue microstructures in vivo, in real time and at a cellular level,” said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies. “This new study with the Cellvizio and the Monarch platforms is designed to demonstrate the feasibility and safety as well as the unique capability to visualize lung lesions outside the airways, where 85% of lesions reside, and could further facilitate the ability of the Monarch Platform to conduct more targeted biopsies.”
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, and China. For more information on Mauna Kea Technologies, visit www.maunakeatech.com
This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on July 12, 2019 under number D.19-0683 and available on the Company's website (www.maunakeatech.com), and to the development of economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.
1 The legal entity of the Lung Cancer Initiative at Johnson & Johnson is Johnson & Johnson Enterprise Innovation, Inc.
2 Needle-based confocal laser endomicroscopy (nCLE) for real-time diagnosing and staging of lung cancer. L. Wijmans, J. Yared, D.M. de Bruin, S.L. Meijer, P. Baas, P.I. Bonta, J.T. Annema. European Respiratory Journal 2019; DOI: 10.1183/13993003.01520-2018